Survivorship after lasting benefit from immunotherapy for advanced cancer
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
This project follows people with advanced cancers who have had long-lasting benefit from immunotherapy to track their health, symptoms, and care needs over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11168670 on NIH RePORTER |
What this research studies
If you join, researchers will look back at medical records from about 8,860 patients treated with immune checkpoint inhibitors between 2014 and 2022 to find people who had durable responses. They will also enroll and actively follow about 1,200 people with advanced lung cancer, kidney cancer, or melanoma who have had a lasting response to these drugs. Clinical information and patient-reported surveys will be collected at enrollment and every six months to map long-term survival, physical symptoms, and psychosocial needs. The team will use these combined data to learn which factors link to lasting benefit and what supports survivors need.
Who could benefit from this research
Good fit: Ideal candidates are adults with advanced lung cancer, kidney cancer, or melanoma who had a partial or complete response to an immune checkpoint inhibitor and have lived at least one year after starting that treatment.
Not a fit: People who never received immune checkpoint inhibitors, who did not have a durable response, or whose cancer types are not part of the prospective cohort may not directly benefit from this project.
Why it matters
Potential benefit: If successful, this work could help tailor follow-up care and symptom support for people who live long after immunotherapy.
How similar studies have performed: Immune checkpoint inhibitors are already known to produce durable remissions for some patients, but large multi-institutional follow-up efforts focused on survivorship and symptom trajectories are limited, making this work relatively novel.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Hahn, Theresa E — Roswell Park Cancer Institute Corp
- Study coordinator: Hahn, Theresa E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.